MX2019002732A - Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata. - Google Patents

Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.

Info

Publication number
MX2019002732A
MX2019002732A MX2019002732A MX2019002732A MX2019002732A MX 2019002732 A MX2019002732 A MX 2019002732A MX 2019002732 A MX2019002732 A MX 2019002732A MX 2019002732 A MX2019002732 A MX 2019002732A MX 2019002732 A MX2019002732 A MX 2019002732A
Authority
MX
Mexico
Prior art keywords
drug conjugates
antibody drug
amino acid
dolastatin analogs
prostate
Prior art date
Application number
MX2019002732A
Other languages
English (en)
Inventor
Richard S Barnett
Nick Knudsen
Andrew Beck
Marco Gymnopoulos
Feng Tian
Ying Sun
Anna- Maria A Hays Putnam
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of MX2019002732A publication Critical patent/MX2019002732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a anticuerpos y conjugados anticuerpo-fármaco de antígeno de membrana específico de próstata (PSMA) que comprenden al menos un aminoácido no naturalmente codificado. Se describen en la presente anticuerpos aPSMA con uno o más aminoácidos no naturalmente codificados y se describen además conjugados anticuerpo-fármaco en donde los anticuerpos aPSMA de la invención se conjugan a una o más toxinas. También se describen en la presente análogos de dolastatina de aminoácidos no naturales que se modifican adicionalmente de manera post-traduccional, métodos para efectuar tales modificaciones y métodos para purificar tales análogos de dolastatina. Típicamente, los análogos de dolastatina modificados incluyen al menos un grupo oxima, carbonilo, dicarbonilo y/o hidroxilamina. Además se describen métodos para utilizar tales conjugados anticuerpo fármaco de aminoácidos no naturales, análogos de dolastatina y análogos de dolastatina de aminoácidos no naturales modificados, incluyendo los usos terapéuticos, de diagnóstico y otros biotecnológicos.
MX2019002732A 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata. MX2019002732A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261656883P 2012-06-07 2012-06-07

Publications (1)

Publication Number Publication Date
MX2019002732A true MX2019002732A (es) 2023-02-23

Family

ID=48699944

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014015029A MX363116B (es) 2012-06-07 2013-06-07 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
MX2019002732A MX2019002732A (es) 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
MX2023010485A MX2023010485A (es) 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014015029A MX363116B (es) 2012-06-07 2013-06-07 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010485A MX2023010485A (es) 2012-06-07 2014-12-05 Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.

Country Status (14)

Country Link
US (2) US10800856B2 (es)
EP (2) EP2858676B1 (es)
JP (1) JP6425650B2 (es)
KR (1) KR102143664B1 (es)
CN (3) CN104619349B (es)
AU (2) AU2013270686B2 (es)
CA (1) CA2874854C (es)
DK (1) DK2858676T3 (es)
ES (1) ES2725329T3 (es)
IL (3) IL235895B (es)
MX (3) MX363116B (es)
NZ (2) NZ703298A (es)
SG (2) SG11201408153YA (es)
WO (1) WO2013185117A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
WO2013173393A1 (en) 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
NZ703581A (en) * 2012-06-19 2016-09-30 Ambrx Inc Anti-cd70 antibody drug conjugates
EP3590922A1 (en) 2013-03-15 2020-01-08 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
CN106132431A (zh) 2013-10-15 2016-11-16 索伦托治疗有限公司 具有靶向分子和两种不同药物的药物偶联物
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
CN106459162A (zh) 2013-12-27 2017-02-22 酵活有限公司 Var2csa‑药物偶联物
UA120364C2 (uk) 2014-04-25 2019-11-25 Пьєр Фабр Медікамент Кон'югат антитіла до igf-1r з лікарським засобом
HUE047952T2 (hu) 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
CN113416229A (zh) 2014-09-17 2021-09-21 酵活有限公司 细胞毒性和抗有丝***化合物、及其使用方法
CN107206101B (zh) * 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
JP6871858B2 (ja) 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
JP2018512377A (ja) * 2015-02-15 2018-05-17 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． リガンド‐細胞傷害性薬物複合体、その製造方法、及びその使用
TWI715611B (zh) 2015-08-14 2021-01-11 美商Ｒｃ生物科技公司 抗體藥物偶聯物的共價鍵連接子及其製備方法與應用
US10233212B2 (en) 2015-11-03 2019-03-19 Industrial Technology Research Institute Compounds, linker-drugs and ligand-drug conjugates
US10548986B2 (en) 2016-03-02 2020-02-04 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
CN110099682B (zh) * 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3630977B1 (en) 2017-06-02 2024-02-21 Ambrx, Inc. Methods and compositions for promoting non-natural amino acid-containing protein production
JP2021519076A (ja) 2018-03-29 2021-08-10 アンブルックス, インコーポレイテッドAmbrx, Inc. ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体
CN109232712B (zh) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的中间体的制备方法
CN111328333B (zh) * 2019-09-29 2023-10-03 烟台迈百瑞国际生物医药股份有限公司 一种酸法制备抗体药物偶联物中间体的方法及其应用
WO2021056754A1 (zh) * 2019-09-29 2021-04-01 烟台迈百瑞国际生物医药股份有限公司 一种酸法制备抗体药物偶联物中间体的方法及其应用
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US971A (en) 1838-10-08 Mode of pbeventing dust from rising from threshing-machines when in
US7850A (en) 1850-12-24 Improvement in the manufacture of starch from maize
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
ATE279430T1 (de) 1998-03-05 2004-10-15 Chiron Corp Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
EP3184539A3 (en) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
WO2004058946A2 (en) 2002-12-22 2004-07-15 The Scripps Research Institute Protein arrays
EP1756166A4 (en) 2004-04-19 2008-08-27 Proscan Rx Pharma DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
US7517903B2 (en) * 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
CN108047086B (zh) * 2004-12-22 2023-06-16 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途
US7638491B2 (en) * 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
JP5249587B2 (ja) 2005-02-18 2013-07-31 メダレックス， インク． フコシル残基を欠く前立腺特異的膜抗原（ｐｓｍａ）に対するモノクローナル抗体
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
EP1874342B1 (en) * 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
CA2612762C (en) * 2005-06-20 2013-12-10 Psma Development Company, Llc Psma antibody-drug conjugates
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
CN101578264A (zh) * 2006-12-18 2009-11-11 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
EP2727606A3 (en) * 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
CN107022020A (zh) * 2008-09-26 2017-08-08 Ambrx公司 修饰的动物***多肽和其用途
JP6581774B2 (ja) * 2011-05-27 2019-09-25 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法
EP3170821B1 (en) * 2011-05-27 2021-09-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates

Also Published As

Publication number Publication date
WO2013185117A1 (en) 2013-12-12
CN108727466A (zh) 2018-11-02
IL235895B (en) 2018-05-31
AU2017200877A1 (en) 2017-03-02
MX363116B (es) 2019-03-11
JP6425650B2 (ja) 2018-11-21
ES2725329T3 (es) 2019-09-23
CN108727466B (zh) 2023-04-28
AU2017200877B2 (en) 2018-08-30
US20150152190A1 (en) 2015-06-04
US20220033518A1 (en) 2022-02-03
MX2014015029A (es) 2015-03-03
DK2858676T3 (da) 2019-05-13
CN116514899A (zh) 2023-08-01
SG10201702176XA (en) 2017-04-27
MX2023010485A (es) 2023-09-18
IL268538A (en) 2019-09-26
IL258937A (en) 2018-06-28
EP2858676B1 (en) 2019-03-13
AU2013270686B2 (en) 2016-11-10
US10800856B2 (en) 2020-10-13
IL235895A0 (en) 2015-01-29
EP3536700A1 (en) 2019-09-11
NZ713941A (en) 2017-02-24
CN104619349A (zh) 2015-05-13
CA2874854A1 (en) 2013-12-12
CA2874854C (en) 2023-03-14
AU2013270686A1 (en) 2015-01-22
IL258937B (en) 2019-08-29
CN104619349B (zh) 2018-07-10
IL268538B (en) 2020-11-30
KR102143664B1 (ko) 2020-08-11
KR20150023563A (ko) 2015-03-05
SG11201408153YA (en) 2015-01-29
EP2858676A1 (en) 2015-04-15
JP2015521590A (ja) 2015-07-30
NZ703298A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
MX2019002732A (es) Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
MX2013013683A (es) Composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales.
MX2020001231A (es) Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
PH12020500308A1 (en) Preparation of therapeautic exosomes using membrane proteins
NZ705370A (en) Fcγriib-specific fc region variant
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2015031673A3 (en) Cns-targetedconjugates of antibodies
MX359954B (es) Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado.
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
EP4276180A3 (en) Clostridium histolyticum enzyme
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
MY172458A (en) Therapeutic agent or prophylactic agent for dementia
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
NZ724828A (en) Nucleophilic catalysts for oxime linkage
UA107836C2 (uk) Метод лікування хвороби альцгеймера
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
EA201300128A1 (ru) Комбинированная фармацевтическая композиция и способы лечения заболеваний или состояний, связанных с нарушением функции сердечно-сосудистой системы
UA99801C2 (ru) Белковая конструкция, которая включает модифицированный полипептид casb7439
WO2012172151A3 (es) PÉPTIDO ANTIGÉNICO AISLADO DERIVADO DE LA PROTEíNA S100-BETA, PROCEDIMIENTO DE IDENTIFICACiÓN Y SU USO EN LA PREVENCiÓN, TRATAMIENTO, DIAGNÓSTICO Y/O SEGUIMIENTO DE LA DIABETES TIPO 1
EA202090685A1 (ru) Нуклеофильные катализаторы для оксимного связывания
WO2011156694A3 (en) Enrichment and purification of infectious prion proteins